Literature DB >> 29771531

Exosomes as a Drug Delivery System in Cancer Therapy: Potential and Challenges.

Golam Kibria, Erika K Ramos, Yong Wan, David R Gius, Huiping Liu.   

Abstract

Exosomes play a pivotal role in mediating intercellular communications and package delivery. They have recently been discovered to serve as diagnostic biomarkers as well as a possible drug delivery vehicle based on their nanometer size range and capability to transfer biological materials to recipient cells. Their unique biocompatibility, high stability, preferred tumor homing, and adjustable targeting efficiency can make exosomes an attractive and potentially effective tool of drug delivery in cancer therapy. While exosomes possess properties that make them uniquely suitable for delivery of bioactive molecules, there remains a to-be-filled gap between the current understanding about exosome biology and the ideal application scenarios. In this review, we summarize the characteristics enabling the potential of exosomes for drug delivery as well as the outstanding questions related to exosome composition and function, production and purification, bioengineering and targeting, uptake and biodistribution, efficacy and immune regulation, etc. Advanced technologies are demanded to visualize, characterize, and sort heterogeneous exosome populations. We are positive that the deeper and more comprehensive understanding of exosome biology as well as advanced nanotechnology will certainly accelerate its therapeutic applications.

Entities:  

Keywords:  biodistribution; drug delivery system; exosomes; tumor homing

Mesh:

Year:  2018        PMID: 29771531      PMCID: PMC6546090          DOI: 10.1021/acs.molpharmaceut.8b00277

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  104 in total

1.  Kaposi's sarcoma: DaunoXome approved.

Authors: 
Journal:  AIDS Treat News       Date:  1996-05-03

2.  Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles.

Authors:  C Théry; M Boussac; P Véron; P Ricciardi-Castagnoli; G Raposo; J Garin; S Amigorena
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

3.  Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.

Authors:  Ian Del Conde; Corie N Shrimpton; Perumal Thiagarajan; José A López
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

Review 4.  Exosome-based immunotherapy.

Authors:  Nathalie Chaput; Julien Taïeb; Noël E C Schartz; Fabrice André; Eric Angevin; Laurence Zitvogel
Journal:  Cancer Immunol Immunother       Date:  2004-01-16       Impact factor: 6.968

5.  Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.

Authors:  Nathalie Chaput; Nöel E C Schartz; Fabrice André; Julien Taïeb; Sophie Novault; Pierre Bonnaventure; Nathalie Aubert; Jacky Bernard; François Lemonnier; Miriam Merad; Gosse Adema; Malcolm Adams; Maria Ferrantini; Antoine F Carpentier; Bernard Escudier; Thomas Tursz; Eric Angevin; Laurence Zitvogel
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

6.  Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells.

Authors:  Adrian E Morelli; Adriana T Larregina; William J Shufesky; Mara L G Sullivan; Donna Beer Stolz; Glenn D Papworth; Alan F Zahorchak; Alison J Logar; Zhiliang Wang; Simon C Watkins; Louis D Falo; Angus W Thomson
Journal:  Blood       Date:  2004-07-29       Impact factor: 22.113

7.  Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation.

Authors:  Richard Wubbolts; Rachel S Leckie; Peter T M Veenhuizen; Guenter Schwarzmann; Wiebke Möbius; Joerg Hoernschemeyer; Jan-Willem Slot; Hans J Geuze; Willem Stoorvogel
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

8.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Authors:  Michael A Morse; Jennifer Garst; Takuya Osada; Shubi Khan; Amy Hobeika; Timothy M Clay; Nancy Valente; Revati Shreeniwas; Mary Ann Sutton; Alain Delcayre; Di-Hwei Hsu; Jean-Bernard Le Pecq; H Kim Lyerly
Journal:  J Transl Med       Date:  2005-02-21       Impact factor: 5.531

Review 9.  Prospects for exosomes in immunotherapy of cancer.

Authors:  G Mignot; S Roux; Clotilde Thery; Elodie Ségura; L Zitvogel
Journal:  J Cell Mol Med       Date:  2006 Apr-Jun       Impact factor: 5.310

10.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.

Authors:  Bernard Escudier; Thierry Dorval; Nathalie Chaput; Fabrice André; Marie-Pierre Caby; Sophie Novault; Caroline Flament; Christophe Leboulaire; Christophe Borg; Sebastian Amigorena; Catherine Boccaccio; Christian Bonnerot; Olivier Dhellin; Mojgan Movassagh; Sophie Piperno; Caroline Robert; Vincent Serra; Nancy Valente; Jean-Bernard Le Pecq; Alain Spatz; Olivier Lantz; Thomas Tursz; Eric Angevin; Laurence Zitvogel
Journal:  J Transl Med       Date:  2005-03-02       Impact factor: 5.531

View more
  51 in total

1.  Microfluidic on-demand engineering of exosomes towards cancer immunotherapy.

Authors:  Zheng Zhao; Jodi McGill; Pamela Gamero-Kubota; Mei He
Journal:  Lab Chip       Date:  2019-05-14       Impact factor: 6.799

Review 2.  Extracellular vesicles in pharmacology: Novel approaches in diagnostics and therapy.

Authors:  Zainuddin Quadri; Ahmed Elsherbini; Erhard Bieberich
Journal:  Pharmacol Res       Date:  2021-12-02       Impact factor: 7.658

Review 3.  Advances of exosome isolation techniques in lung cancer.

Authors:  Elham O Mahgoub; Ehsan Razmara; Amirreza Bitaraf; Fahimeh-Sadat Norouzi; Maryam Montazeri; Roudabeh Behzadi-Andouhjerdi; Mojtaba Falahati; Ke Cheng; Yousif Haik; Anwarul Hasan; Sadegh Babashah
Journal:  Mol Biol Rep       Date:  2020-08-12       Impact factor: 2.316

Review 4.  Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.

Authors:  Leila Pourtalebi Jahromi; Mohammad-Ali Shahbazi; Aziz Maleki; Amir Azadi; Hélder A Santos
Journal:  Adv Sci (Weinh)       Date:  2021-03-01       Impact factor: 16.806

Review 5.  Small extracellular vesicles in cancer.

Authors:  Komal Abhange; Amy Makler; Yi Wen; Natasha Ramnauth; Wenjun Mao; Waseem Asghar; Yuan Wan
Journal:  Bioact Mater       Date:  2021-04-07

Review 6.  Nanoplatforms for Sepsis Management: Rapid Detection/Warning, Pathogen Elimination and Restoring Immune Homeostasis.

Authors:  Gan Luo; Jue Zhang; Yaqi Sun; Ya Wang; Hanbin Wang; Baoli Cheng; Qiang Shu; Xiangming Fang
Journal:  Nanomicro Lett       Date:  2021-03-08

Review 7.  Stimuli-responsive nanocarriers for therapeutic applications in cancer.

Authors:  Xubo Zhao; Jie Bai; Wenjing Yang
Journal:  Cancer Biol Med       Date:  2021-03-25       Impact factor: 4.248

Review 8.  Insights Into Exosomal Non-Coding RNAs Sorting Mechanism and Clinical Application.

Authors:  Yi Qiu; Peiyao Li; Zuping Zhang; Minghua Wu
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

Review 9.  Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs).

Authors:  Weina Ke; Kirill A Afonin
Journal:  Adv Drug Deliv Rev       Date:  2021-06-16       Impact factor: 17.873

10.  Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo.

Authors:  Ying Wang; Mimi Guo; Dingmei Lin; Dajun Liang; Ling Zhao; Ruizhi Zhao; Yan Wang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.